Sarcoma  >>  Aliqopa (copanlisib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aliqopa (copanlisib) / Bayer
NCT03458728 / 2017-000383-15: Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Terminated
1/2
31
US
Copanlisib (BAY806946)
Bayer, Bayer AG
Relapsed or Refractory Solid Tumors or Lymphoma in Children, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma
02/23
02/23

Download Options